Unique ID issued by UMIN | UMIN000049139 |
---|---|
Receipt number | R000055976 |
Scientific Title | Evaluation of the safety and efficacy of lascufloxacin for Legionella pneumonia |
Date of disclosure of the study information | 2022/10/06 |
Last modified on | 2022/10/06 13:12:54 |
Evaluation of the safety and efficacy of lascufloxacin for Legionella pneumonia
Safety and efficacy of lascufloxacin for Legionella
Evaluation of the safety and efficacy of lascufloxacin for Legionella pneumonia
Safety and efficacy of lascufloxacin for Legionella
Japan |
Legionella pneumonia
Medicine in general | Pneumology | Infectious disease |
Others
NO
To evaluate the safety and efficacy of lascufloxacin for Legionella pneumonia
Safety,Efficacy
1. 30-day mortality
2. In-hospital mortality
1. Duration of admission
2. Pneumonia recurrence requiring antibiotic therapy
3. Time to defervescence from start of lascufloxacin (Defervescence was defined in days after the first 24 hours from less than 37.8 degree Celsius or less than 37.0 degree Celsius)
4. Intensive care unit admission, ventilatory support and vasopressor use due to exacerbation of pneumonia
5. Adverse drug effects
Observational
15 | years-old | <= |
Not applicable |
Male and Female
Hospitalized patients, aged 15 years or more, diagnosed with Legionella pneumonia.
Community-onset pneumonia patients.
Patients who consent to participation in the study (consent by proxy is permitted).
Patients treated with antibiotics other than lascufloxacin.
25
1st name | Akihiro |
Middle name | |
Last name | Ito |
Ohara Healthcare Foundation, Kurashiki Central Hospital
Department of Respiratory Medicine
710-8602
Miwa 1-1-1, Kurashiki, Okayama
086-422-0210
ai12306@kchnet.or.jp
1st name | Akihiro |
Middle name | |
Last name | Ito |
Ohara Healthcare Foundation, Kurashiki Central Hospital
Department of Respiratory Medicine
710-8602
Miwa 1-1-1, Kurashiki, Okayama
086-422-0210
ai12306@kchnet.or.jp
Ohara Healthcare Foundation, Kurashiki Central Hospital, Department of Respiratory Medicine
Ohara Healthcare Foundation, Kurashiki Central Hospital
Self funding
Japan
Kurashiki Central Hospital Ethics Committee
Miwa 1-1-1, Kurashiki, Okayama
086-422-0210
ai12306@kchnet.or.jp
NO
2022 | Year | 10 | Month | 06 | Day |
Unpublished
Open public recruiting
2022 | Year | 08 | Month | 22 | Day |
2022 | Year | 09 | Month | 13 | Day |
2022 | Year | 10 | Month | 06 | Day |
2025 | Year | 12 | Month | 31 | Day |
This study is designed as a prospective observational study.
All hospitalized patients with Legionella pneumonia treated using lascufloxacin will be enrolled.
In all patients, the following clinical data will be investigated:
age, sex, smoking habit, comorbidities, history of visiting a hot spring or spa, history of soil exposure, symptoms, oral medicines, vital signs, blood tests, microbiological tests, chest radiological examinations, severity of pneumonia (A-DROP, CURB-65, Pneumonia Severity Index), treatment, and prognosis.
To evaluate the safety and efficacy of lascufloxacin, we plan to compare the study subjects with Legionella pneumonia patients treated using levofloxacin as a historical control.
2022 | Year | 10 | Month | 06 | Day |
2022 | Year | 10 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000055976
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |